Arcadia Biosciences Reports Q2 Loss of $4.5 Million, Revenue of $1.5 Million.
ByAinvest
Friday, Aug 15, 2025 5:12 am ET1min read
RKDA--
Arcadia's adjusted earnings per share (EPS) were 2 cents for the quarter, down from 16 cents in Q2 2024. The company's gross margins have consistently exceeded 30% for ten consecutive quarters, indicating strong operational efficiency. However, total operating expenses rose dramatically by 390% in Q2 2025, suggesting escalating costs could impact future profitability [1].
Arcadia also announced the receipt of 2.7 million shares of stock in Above Food Ingredients Inc. as partial repayment related to a previous sale. This, along with the elimination of $1 million in contingent liabilities, brings the total eliminated to $2 million year-to-date [1]. The company continues to pursue the repayment of the remaining outstanding balance of the note receivable related to the sale of GoodWheat™ assets.
Arcadia's pending business combination with Roosevelt Resources continues to move forward. The company recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources [1].
References:
[1] https://www.quiverquant.com/news/Arcadia+Biosciences+Reports+11%25+Revenue+Growth+Driven+by+24%25+Increase+in+Zola%C2%AE+Sales+and+Reduces+Liabilities+by+%241+Million
Arcadia Biosciences reported a Q2 loss of $4.5 million, or $3.26 per share, and revenue of $1.5 million. The agricultural biotechnology trait company's adjusted earnings per share were 2 cents.
Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, reported its financial results for the second quarter and first half of 2025. The company experienced an 11% increase in total revenues year over year, driven by a significant 24% growth in Zola® coconut water sales. Despite this revenue growth, Arcadia reported a net loss of $4.5 million for the second quarter, an increase from the net income of $1.1 million in Q2 2024 [1].Arcadia's adjusted earnings per share (EPS) were 2 cents for the quarter, down from 16 cents in Q2 2024. The company's gross margins have consistently exceeded 30% for ten consecutive quarters, indicating strong operational efficiency. However, total operating expenses rose dramatically by 390% in Q2 2025, suggesting escalating costs could impact future profitability [1].
Arcadia also announced the receipt of 2.7 million shares of stock in Above Food Ingredients Inc. as partial repayment related to a previous sale. This, along with the elimination of $1 million in contingent liabilities, brings the total eliminated to $2 million year-to-date [1]. The company continues to pursue the repayment of the remaining outstanding balance of the note receivable related to the sale of GoodWheat™ assets.
Arcadia's pending business combination with Roosevelt Resources continues to move forward. The company recently filed an amendment to the initial Form S-4 registration statement to provide responses to comments received from the SEC and to provide updated financial information through the first quarter of 2025 for both Arcadia Biosciences and Roosevelt Resources [1].
References:
[1] https://www.quiverquant.com/news/Arcadia+Biosciences+Reports+11%25+Revenue+Growth+Driven+by+24%25+Increase+in+Zola%C2%AE+Sales+and+Reduces+Liabilities+by+%241+Million

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet